Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenues $ 7,000,000 $ 7,000,000
Expenses:        
Research and development 7,978,000 7,969,000 22,624,000 20,896,000
General and administrative 6,092,000 4,432,000 18,117,000 16,382,000
Depreciation and amortization 802,000 847,000 2,443,000 3,746,000
Licensed technology impairment charge 32,916,000
Total expenses 14,872,000 13,248,000 43,184,000 73,940,000
Loss from operations (14,872,000) (6,248,000) (43,184,000) (66,940,000)
Gain on settlement with licensor 6,743,000 6,743,000
PPP loan payable forgiveness income 1,758,000 1,758,000
Interest and miscellaneous income 10,000 338,000 33,000 1,261,000
Interest expense (683,000) (1,327,000) (3,603,000) (2,727,000)
Net loss $ (7,044,000) $ (7,237,000) $ (38,253,000) $ (68,406,000)
Basic and diluted loss per common share $ (0.07) $ (0.08) $ (0.40) $ (0.74)
Weighted average number of common shares outstanding – basic and diluted 97,990,338 92,714,983 96,258,681 92,594,339
Other comprehensive income/(loss):        
Change in unrealized gains/(losses) related to available-for-sale debt securities $ 1,000 $ (116,000) $ 10,000 $ 17,000
Foreign currency translation adjustments (9,000) (9,000)
Comprehensive loss $ (7,052,000) $ (7,353,000) $ (38,252,000) $ (68,389,000)